SMS Pharmaceuticals (BOM:532815) EBIT : ₹1,038 Mil (TTM As of Dec. 2024)

View and export this data going back to 2007. Start your Free Trial

What is SMS Pharmaceuticals EBIT?

SMS Pharmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2024 was ₹266 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2024 was ₹1,038 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. SMS Pharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2024 was 8.30%. SMS Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 12.70%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. SMS Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 5.03%.

SMS Pharmaceuticals EBIT Historical Data

The historical data trend for SMS Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SMS Pharmaceuticals EBIT Chart

SMS Pharmaceuticals Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

EBIT

Get a 7-Day Free Trial

619.49

1,013.73

866.56

263.44

887.25

SMS Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EBIT	Get a 7-Day Free Trial															224.80	265.08	264.97	241.49	266.42

Competitive Comparison of SMS Pharmaceuticals's EBIT

For the Drug Manufacturers - General subindustry, SMS Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SMS Pharmaceuticals's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SMS Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where SMS Pharmaceuticals's EV-to-EBIT falls into.

Save Embed

;

Save Embed

;

SMS Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,038 Mil.

SMS Pharmaceuticals (BOM:532815) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

SMS Pharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2024 is calculated as:

	ROC % (Q: Dec. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2024 )	+	Invested Capital (Q: Dec. 2024 ))	/ count )
=	980.548 * ( 1 - 23.89% )	/	( (8987.055	+	0)	/ 1 )
=	746.2950828	/	8987.055
=	8.30 %

where

	Invested Capital		(Q: Sep. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	11347.282	-	2151.316	-	( 208.911	-	max(0, 3753.988	-	5819.422	+	208.911	))
=	8987.055

	Invested Capital		(Q: Dec. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0	-	0	-	( 0	-	max(0, 0	-	0	+	0	))
=	0

Note: The Operating Income data used here is four times the quarterly (Dec. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

SMS Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2024		Q: Dec. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	1065.672	/	( ( (5184.058 + max(3203.823, 0))	+	(0 + max(0, 0)) )	/	1 )
=	1065.672	/	( ( 8387.881	+	0 )	/	1 )
=	1065.672	/	8387.881
=	12.70 %

where Working Capital is:

	Working Capital		(Q: Sep. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(2133.788	+	3152.716	+	324.007)	-	(2151.316	+	0	+	255.372)
=	3203.823

	Working Capital		(Q: Dec. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0)	-	(0	+	0	+	0)
=	0

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

SMS Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2024 )
	=	1037.963	/	20650.008
	=	5.03 %

SMS Pharmaceuticals EBIT Related Terms

Thank you for viewing the detailed overview of SMS Pharmaceuticals's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

SMS Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SMS Pharmaceuticals Ltd (BOM:532815) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

SMSPHARMA:India

Address

Plot No. 72, H.No. 8-2-334/3&4, Road. No. 5, Opposite SBI Executive Enclave, Banjara Hills, Hyderabad, TG, IND, 500034

Website

https://www.smspharma.com

SMS Pharmaceuticals Ltd is a drug manufacturing company. It is engaged in the manufacturing and sale of active pharmaceutical ingredients (API's), and their intermediates viz. Metal Acetylacetonates, Diltiazem Hydrochloride and Taxol C-13 Side Chain. Its product portfolio includes drugs for anti-ulcer, anti-fungal, anti-migraine, anti-diabetic, erectile dysfunction, anti-viral, among others.

SMS Pharmaceuticals Headlines

No Headlines